Published in J Clin Microbiol on November 26, 2008
Multicenter evaluation of a new DNA microarray for rapid detection of clinically relevant bla genes from beta-lactam-resistant gram-negative bacteria. Antimicrob Agents Chemother (2011) 1.29
Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae. J Clin Microbiol (2011) 1.18
Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Clin Infect Dis (2011) 1.11
Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods. Clin Microbiol Rev (2016) 1.05
Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. Antimicrob Agents Chemother (2009) 1.03
Current concepts in laboratory testing to guide antimicrobial therapy. Mayo Clin Proc (2012) 1.00
Escherichia coli β-Lactamases: What Really Matters. Front Microbiol (2016) 0.84
Development of a TaqMan multiplex PCR assay for detection of plasmid-mediated ampC β-lactamase genes. J Clin Microbiol (2012) 0.83
Evaluation of four phenotypic methods to detect plasmid-mediated AmpC β-lactamases in clinical isolates. Eur J Clin Microbiol Infect Dis (2012) 0.77
Overexpression of an outer membrane protein associated with decreased susceptibility to carbapenems in Proteus mirabilis. PLoS One (2015) 0.75
Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients. BMC Infect Dis (2012) 0.75
Optimal phenotypic testing of AmpC beta-lactamases using boronic acid solutions. Eur J Clin Microbiol Infect Dis (2011) 0.75
Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia. Wien Klin Wochenschr (2016) 0.75
A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother (1995) 26.51
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother (2001) 16.97
Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev (2001) 15.81
Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol (2002) 12.53
Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother (2002) 7.73
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis (2001) 4.17
Metallo-beta-lactamases: a class apart. Clin Infect Dis (1998) 3.91
Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis (1999) 3.77
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis (2003) 3.42
Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol (2001) 3.06
AmpC disk test for detection of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal AmpC beta-lactamases. J Clin Microbiol (2005) 2.74
Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. J Clin Microbiol (2005) 2.46
Practical methods using boronic acid compounds for identification of class C beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol (2005) 2.43
Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2004) 2.20
Rapid method of extraction and analysis of extended-spectrum beta-lactamases from clinical strains of Klebsiella pneumoniae. Clin Microbiol Infect (2001) 1.51
Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol (2004) 1.50
Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother (2002) 1.35
Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol (2005) 1.33
Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobacteriaceae. J Clin Microbiol (2004) 1.23
Horizontal transfer of blaCMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19. Antimicrob Agents Chemother (2006) 1.22
Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents (2003) 1.22
Plasmid-borne AmpC beta-lactamases. Can J Microbiol (2002) 1.21
Identification of extended-spectrum, AmpC, and carbapenem- hydrolyzing beta-lactamases in Escherichia coli and Klebsiella pneumoniae by disk tests. J Clin Microbiol (2006) 1.10
Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime. J Antimicrob Chemother (1989) 1.06
Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J Antimicrob Chemother (2004) 0.97
Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study. Diagn Microbiol Infect Dis (1994) 0.96
The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres. J Antimicrob Chemother (1993) 0.87
In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies. Eur J Clin Microbiol Infect Dis (1994) 0.78
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (2009) 25.61
Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev (2005) 15.72
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis (2013) 6.60
Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54
Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother (2006) 4.80
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol (2008) 4.42
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis (2013) 4.07
Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. Antimicrob Agents Chemother (2003) 3.92
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother (2009) 3.82
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis (2006) 3.54
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother (2009) 2.96
"Stormy waters ahead": global emergence of carbapenemases. Front Microbiol (2013) 2.74
Carbapenems: past, present, and future. Antimicrob Agents Chemother (2011) 2.61
Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proc Natl Acad Sci U S A (2014) 2.56
In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother (2002) 2.48
Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis (2012) 2.48
Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother (2009) 2.28
Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother (2005) 2.22
Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (bla KPC) variants. J Clin Microbiol (2010) 2.18
Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother (2011) 2.18
Occurrence, distribution, and origins of Streptococcus pneumoniae Serotype 6C, a recently recognized serotype. J Clin Microbiol (2008) 2.17
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother (2009) 2.12
The continuing challenge of ESBLs. Curr Opin Pharmacol (2007) 2.12
Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med (2012) 2.06
Isolation and characterization of an autoinducer synthase from Acinetobacter baumannii. J Bacteriol (2008) 2.02
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis (2013) 2.01
AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother (2003) 1.98
Emergence in Klebsiella pneumoniae and Enterobacter cloacae clinical isolates of the VIM-4 metallo-beta-lactamase encoded by a conjugative plasmid. Antimicrob Agents Chemother (2004) 1.98
Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis (2008) 1.97
Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother (2003) 1.97
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrob Agents Chemother (2009) 1.96
Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother (2010) 1.94
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.94
Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis. J Biol Chem (2012) 1.93
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother (2008) 1.89
Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother (2005) 1.88
A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother (2005) 1.88
Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother (2010) 1.87
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother (2009) 1.80
AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother (2007) 1.79
IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomonas putida clinical isolate. Antimicrob Agents Chemother (2003) 1.77
The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! Curr Opin Microbiol (2005) 1.77
Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV beta-lactamases. J Clin Microbiol (2002) 1.75
Effect of multiple interventions on community health workers' adherence to clinical guidelines in Siaya district, Kenya. Trans R Soc Trop Med Hyg (2006) 1.75
Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamases. Biochemistry (2007) 1.74
Transmission dynamics of extended-spectrum β-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis (2012) 1.72
Complete nucleotide sequences of blaKPC-4- and blaKPC-5-harboring IncN and IncX plasmids from Klebsiella pneumoniae strains isolated in New Jersey. Antimicrob Agents Chemother (2012) 1.70
Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center. Infect Control Hosp Epidemiol (2011) 1.70
In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother (2006) 1.68
Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J Mol Biol (2003) 1.66
RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist (2007) 1.66
MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother (2007) 1.65
Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J Clin Microbiol (2005) 1.65
Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis (2011) 1.64
Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J Biol Chem (2006) 1.60
Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother (2006) 1.60
Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis (2002) 1.60
Minimizing antimicrobial resistance: the key role of the infectious diseases physician. Clin Infect Dis (2004) 1.59
Complete nucleotide sequence of a blaKPC-harboring IncI2 plasmid and its dissemination in New Jersey and New York hospitals. Antimicrob Agents Chemother (2013) 1.59
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.58
Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother (2005) 1.56
Development and validation of an in vivo Candida albicans biofilm denture model. Infect Immun (2010) 1.56
Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in Gram-negative isolates. J Clin Microbiol (2010) 1.55
Genomewide analysis of divergence of antibiotic resistance determinants in closely related isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2010) 1.55
Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients. J Microbiol Methods (2003) 1.54
First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world. J Clin Microbiol (2012) 1.52
Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob Agents Chemother (2004) 1.52
New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. MBio (2014) 1.51
The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob Agents Chemother (2008) 1.47
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother (2013) 1.47
Multiplex real-time PCR for detection of an epidemic KPC-producing Klebsiella pneumoniae ST258 clone. Antimicrob Agents Chemother (2012) 1.46
"Salvage microbiology": detection of bacteria directly from clinical specimens following initiation of antimicrobial treatment. PLoS One (2013) 1.45
Antimicrobial resistance: international control strategies, with a focus on limited-resource settings. Int J Antimicrob Agents (2008) 1.45
Genetic analysis of surface motility in Acinetobacter baumannii. Microbiology (2011) 1.44
Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of OmpF and OmpC porin analogs. Antimicrob Agents Chemother (2002) 1.44
Extended-spectrum beta-lactamases in multidrug-resistant Escherichia coli: changing the therapy for hospital-acquired and community-acquired infections. Clin Infect Dis (2006) 1.43
Bacteremic sepsis disturbs alveolar perfusion distribution in the lungs of rats. Crit Care Med (2008) 1.42
Vacuum-mixing significantly changes antibiotic elution characteristics of commercially available antibiotic-impregnated bone cements. J Bone Joint Surg Am (2011) 1.42
New Delhi metallo-β-lactamase and multidrug resistance: a global SOS? Clin Infect Dis (2011) 1.41
Beta-lactamases: a survey of protein diversity. Curr Drug Targets Infect Disord (2003) 1.41
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. J Biol Chem (2003) 1.41
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. Antimicrob Agents Chemother (2010) 1.41
What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist Updat (2006) 1.41
Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis (2002) 1.40